Penn Medicine Healthy Heart

Description

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.

Conditions

Hypertension, Hyperlipidemias

Talk to us

Study Overview

On this page

Study Details

Study overview

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.

Reducing Atherosclerotic Cardiovascular Disease (ASCVD) Through a Comprehensive Heart Disease Prevention Program (HDPP)

Penn Medicine Healthy Heart

Condition
Hypertension
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Penn Medicine, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * On the Penn Medicine Primary Care Service Line registry
  • * Last 2 Blood Pressure readings with Systolic Blood Pressure \>=140 from any outpatient encounter in the last 12 months AND
  • * ASCVD dx OR ASCVD risk score ≥10% OR Diabetes dx OR A1c ≥6.5 in last year OR Diabetes registry OR Last LDL ≥190 in past five years AND
  • * Not on a statinor PCSK9, Inclisiran OR on a Low-intensity/moderate-intensity statin) with LDL \>100
  • * Patients on PCSK9 inhibitors
  • * Documented statin allergy/ or intolerance in the EMR
  • * Pregnancy
  • * Breast feeding
  • * Markedly shortened life expectancy including:
  • 1. metastatic cancer
  • 2. hospice
  • 3. End Stage Renal Disease
  • 4. Congestive Heart Failure
  • 5. Dementia
  • * Is a non-English speaker requiring a translator
  • * Patients who do not have a cell phone

Ages Eligible for Study

35 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pennsylvania,

Kevin Volpp, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2025-06